HealthCor Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

HealthCor Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-7,510	Closed	-$1.42M	–	70
2021 Q3	$1.42M	Buy	+7,510	New	+$1.41M	0.06%	63
2019 Q3	–	Sell	-468,540	Closed	-$34M	–	56
2019 Q2	$34M	Buy	+468,540	New	+$35.9M	1.32%	31

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

HealthCor Management's ALNY Position: Q4 2021 in Review

HealthCor Management sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2021, closing a stake of 7,510 shares — an estimated $1.42M sold.

HealthCor Management first reported a position in ALNY in Q2 2019 and held it in 2 quarters. The position peaked at $34M in Q2 2019. 435 funds tracked by Wall St. Rank hold ALNY as of Q4 2021.

HealthCor Management reported no remaining Alnylam Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
HealthCor Management sold 7,510 Alnylam Pharmaceuticals shares in Q4 2021, an estimated $1.42M.
HealthCor Management first reported a position in Alnylam Pharmaceuticals in Q2 2019 and held it in 2 quarters.
HealthCor Management's Alnylam Pharmaceuticals position peaked at $34M in Q2 2019.
435 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2021.

Based on HealthCor Management's 13F filing for Q4 2021, filed 14 Feb 2022.